vs
美国国际集团（AII）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是美国国际集团的1.0倍（$69.8M vs $68.1M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 30.7%，领先353.4%）
美国国际集团（AIG）是一家美国跨国金融保险集团，业务遍及全球80多个国家和地区，截至2023年共有雇员25200人。集团核心业务分为三大板块：一般保险、人寿与退休服务，另设有一家独立的科技赋能子公司。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
AII vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.0倍
$68.1M
净利率更高
RIGL
高出353.4%
30.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.1M | $69.8M |
| 净利润 | $20.9M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 43.0% | 33.2% |
| 净利率 | 30.7% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.58 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIIRIGL
| Q4 25 | $68.1M | $69.8M | ||
| Q3 25 | $62.0M | $69.5M | ||
| Q2 25 | $74.5M | $101.7M | ||
| Q1 25 | $71.9M | $53.3M | ||
| Q4 24 | — | $57.6M | ||
| Q3 24 | — | $55.3M | ||
| Q2 24 | — | $36.8M | ||
| Q1 24 | — | $29.5M |
净利润AIIRIGL
| Q4 25 | $20.9M | $268.1M | ||
| Q3 25 | $13.2M | $27.9M | ||
| Q2 25 | $27.5M | $59.6M | ||
| Q1 25 | $38.1M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-8.2M |
毛利率AIIRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率AIIRIGL
| Q4 25 | 43.0% | 33.2% | ||
| Q3 25 | 30.3% | 40.9% | ||
| Q2 25 | 32.3% | 60.1% | ||
| Q1 25 | 59.7% | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率AIIRIGL
| Q4 25 | 30.7% | 384.0% | ||
| Q3 25 | 21.2% | 40.2% | ||
| Q2 25 | 36.9% | 58.6% | ||
| Q1 25 | 53.0% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | — | 22.5% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | — | -27.9% |
每股收益（稀释后）AIIRIGL
| Q4 25 | $0.58 | $14.11 | ||
| Q3 25 | $0.67 | $1.46 | ||
| Q2 25 | $1.62 | $3.28 | ||
| Q1 25 | $2.78 | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.0M | $155.0M |
| 总债务越低越好 | $618.0K | $52.5M |
| 股东权益账面价值 | $337.0M | $391.5M |
| 总资产 | $1.2B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资AIIRIGL
| Q4 25 | $222.0M | $155.0M | ||
| Q3 25 | $171.9M | $137.1M | ||
| Q2 25 | $259.6M | $108.4M | ||
| Q1 25 | $236.4M | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $49.5M |
总债务AIIRIGL
| Q4 25 | $618.0K | $52.5M | ||
| Q3 25 | $721.0K | $60.0M | ||
| Q2 25 | $824.0K | $60.0M | ||
| Q1 25 | $926.0K | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益AIIRIGL
| Q4 25 | $337.0M | $391.5M | ||
| Q3 25 | $315.9M | $117.6M | ||
| Q2 25 | $301.9M | $81.9M | ||
| Q1 25 | $186.1M | $18.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-29.9M | ||
| Q1 24 | — | $-31.7M |
总资产AIIRIGL
| Q4 25 | $1.2B | $513.6M | ||
| Q3 25 | $1.4B | $242.5M | ||
| Q2 25 | $1.6B | $206.7M | ||
| Q1 25 | $1.1B | $176.0M | ||
| Q4 24 | — | $164.0M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | — | $128.4M | ||
| Q1 24 | — | $126.5M |
负债/权益比AIIRIGL
| Q4 25 | 0.00× | 0.13× | ||
| Q3 25 | 0.00× | 0.51× | ||
| Q2 25 | 0.00× | 0.73× | ||
| Q1 25 | 0.00× | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $138.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $133.2M | — |
| 自由现金流率自由现金流/营收 | 195.6% | — |
| 资本支出强度资本支出/营收 | 7.4% | — |
| 现金转化率经营现金流/净利润 | 6.62× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $216.1M | — |
8季度趋势，按日历期对齐
经营现金流AIIRIGL
| Q4 25 | $138.2M | $22.0M | ||
| Q3 25 | $-7.5M | $24.0M | ||
| Q2 25 | $27.4M | $30.5M | ||
| Q1 25 | $68.1M | $-893.0K | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | — | $302.0K | ||
| Q1 24 | — | $-5.0M |
自由现金流AIIRIGL
| Q4 25 | $133.2M | — | ||
| Q3 25 | $-11.9M | — | ||
| Q2 25 | $26.9M | — | ||
| Q1 25 | $68.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率AIIRIGL
| Q4 25 | 195.6% | — | ||
| Q3 25 | -19.2% | — | ||
| Q2 25 | 36.1% | — | ||
| Q1 25 | 94.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度AIIRIGL
| Q4 25 | 7.4% | — | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率AIIRIGL
| Q4 25 | 6.62× | 0.08× | ||
| Q3 25 | -0.57× | 0.86× | ||
| Q2 25 | 1.00× | 0.51× | ||
| Q1 25 | 1.79× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
